Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …

GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
被引用次数：126 相关文章

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a" real-world" observational study in the …

GY Lip, X Pan, S Kamble, H Kawabata… - … Journal of Clinical …, 2016 - europepmc.org
Background Limited data are available about the real-world safety of non-vitamin K
antagonist oral anticoagulants (NOACs). Objectives To compare the major bleeding risk …

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a" real-world" observational study in the …

GYH Lip, X Pan, S Kamble… - … journal of clinical …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Limited data are available about the real-world safety of non-vitamin K
antagonist oral anticoagulants (NOACs). Objectives To compare the major bleeding risk …

[引用][C] Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study …

GYH Lip, X Pan, S Kamble, H Kawabata… - International Journal of …, 2016 - cir.nii.ac.jp
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban,
dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States | CiNii …
[PDF] academia.edu

[PDF][PDF] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in …

GYH Lip, X Pan, S Kamble, H Kawabata, J Mardekian… - academia.edu
Background: Limited data are available about the real-world safety of non-vitamin K
antagonist oral anticoagulants (NOACs). Objectives: To compare the major bleeding risk …

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a" real-world" observational study in the …

GYH Lip, X Pan, S Kamble, H Kawabata… - International Journal of …, 2016 - vbn.aau.dk
BACKGROUND: Limited data are available about the real-world safety of non-vitamin K
antagonist oral anticoagulants (NOACs). OBJECTIVES: To compare the major bleeding risk …

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …

GYH Lip, X Pan, S Kamble, H Kawabata… - International Journal of …, 2016 - infona.pl
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
[HTML] nih.gov

[HTML][HTML] Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study …

GYH Lip, X Pan, S Kamble, H Kawabata… - … Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
[PDF] cyberleninka.org

[PDF][PDF] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in …

GYH Lip, X Pan, S Kamble, H Kawabata, J Mardekian… - cyberleninka.org
Background: Limited data are available about the real-world safety of non-vitamin K
antagonist oral anticoagulants (NOACs). Objectives: To compare the major bleeding risk …